Published on May 21, 2024 at 12:25 p.m. / Modified on May 21, 2024 at 2:54 p.m.
Idorsia raises his head a little, but Jean-Paul Clozel leaves his direction. Having become an emblematic figure in Swiss pharma with Actelion, his previous company, the French doctor has had to face in recent months the difficulties which shook the Basel firm, leading to the loss of 475 jobs. On June 13, he will hand over general management to André Muller, current financial director of Idorsia, a position he has held since the creation of the company. A function that he also held within Actelion.
Furthermore, Jean-Paul Clozel announced his intention to stand for election as chairman of the board of directors at this year’s annual general meeting. Its current president, Mathieu Simon, must run for the position of vice-president.
Interested in this item?
To take full advantage of our content, subscribe! Until May 31, take advantage of nearly 15% off the annual offer!
CHECK OFFERS
Good reasons to subscribe to Le Temps:
- Unlimited access to all content available on the website.
- Unlimited access to all content available on the mobile application
- Sharing plan of 5 articles per month
- Consultation of the digital version of the newspaper from 10 p.m. the day before
- Access to supplements and T, the Temps magazine, in e-paper format
- Access to a set of exclusive benefits reserved for subscribers
Already a subscriber?
To log in
#Swiss
